Literature DB >> 19251482

Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs.

Gopinath S Palanisamy1, Nancy DuTeau, Kathleen D Eisenach, Donald M Cave, Susan A Theus, Barry N Kreiswirth, Randall J Basaraba, Ian M Orme.   

Abstract

Virtually all new tuberculosis vaccine candidates are tested in animals using the laboratory strains H37Rv or Erdman. However, naturally occurring M. tuberculosis infections are caused by strains that are widely different in phenotype and genotype. Very little is known about the characteristics of these clinical isolates in terms of basic biology, virulence and in vivo pathogenicity. In this study, we have used a standardized aerosol infection of guinea pigs to compare in vivo differences between clinical strains of M. tuberculosis. Strains consisted of both drug sensitive and multi-drug resistant (MDR) strains of Beijing and non-Beijing varieties. Collectively, these clinical isolates tested in the guinea pig model exhibited a wide range of virulence. Infection with certain isolates caused severe and rapidly progressive pulmonary and extra-pulmonary lesion necrosis, some of which progressed to atypical cavitary lesions in draining mediastinal and tracheobronchial lymph nodes. The two MDR-TB strains used in this study exhibited low level virulence as determined by bacterial growth, lesion scores and survival. Since infections with clinical M. tuberculosis isolates produce such varied disease, it is unknown whether new tuberculosis vaccines being developed will provide the same level of protection as seen when tested using laboratory challenge strains. The use of appropriate animal models allows for this important question to be addressed.

Entities:  

Mesh:

Year:  2009        PMID: 19251482     DOI: 10.1016/j.tube.2009.01.005

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  39 in total

1.  Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

3.  Does M. tuberculosis genomic diversity explain disease diversity?

Authors:  Mireilla Coscolla; Sebastien Gagneux
Journal:  Drug Discov Today Dis Mech       Date:  2010

4.  Epidemiologic consequences of microvariation in Mycobacterium tuberculosis.

Authors:  Barun Mathema; Natalia Kurepina; Guibin Yang; Elena Shashkina; Claudia Manca; Carolina Mehaffy; Helle Bielefeldt-Ohmann; Shama Ahuja; Dorothy A Fallows; Angelo Izzo; Pablo Bifani; Karen Dobos; Gilla Kaplan; Barry N Kreiswirth
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

5.  BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity.

Authors:  Andrew Keyser; Jolynn M Troudt; Jennifer L Taylor; Angelo A Izzo
Journal:  Vaccine       Date:  2011-10-18       Impact factor: 3.641

6.  Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Authors:  Diane J Ordway; Shaobin Shang; Marcela Henao-Tamayo; Andres Obregon-Henao; Laura Nold; Megan Caraway; Crystal A Shanley; Randall J Basaraba; Colleen G Duncan; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 7.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

8.  Origins of a 350-kilobase genomic duplication in Mycobacterium tuberculosis and its impact on virulence.

Authors:  Pilar Domenech; Anya Rog; Jalal-ud-din Moolji; Nicolas Radomski; Ashley Fallow; Lizbel Leon-Solis; Julia Bowes; Marcel A Behr; Michael B Reed
Journal:  Infect Immun       Date:  2014-04-28       Impact factor: 3.441

9.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

10.  Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival.

Authors:  Susanne Homolka; Stefan Niemann; David G Russell; Kyle H Rohde
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.